Description
Avagra (Avanafil) 100 mg
Avagra 100 mg is a product listing for avanafil, an oral phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction in adult men. Regulatory information for avanafil tablets identifies it as a prescription medicine for this condition.
Active Ingredient and Medicine Class
The verified active ingredient is avanafil. It belongs to the PDE5 inhibitor class of medicines. This class also includes other well-known erectile dysfunction treatments such as sildenafil, tadalafil and vardenafil.
Established Medical Uses
Avanafil is established for the treatment of erectile dysfunction. Official product information describes use in adult males with erectile dysfunction, where the medicine helps support an erection in response to sexual stimulation. It is not intended to increase sexual desire.
How It Works
Avanafil works by inhibiting PDE5, an enzyme that breaks down cyclic guanosine monophosphate (cGMP) in penile tissue. By preserving cGMP, it supports the smooth-muscle relaxation and increased blood flow needed for an erection during sexual arousal. Its effect depends on sexual stimulation.
Important Safety Information
Avanafil has important contraindications and interaction risks. It must not be used with organic nitrates, because the combination can cause a dangerous drop in blood pressure. It is also contraindicated in patients with hypersensitivity to the medicine and in those taking strong CYP3A4 inhibitors, which can markedly increase avanafil exposure.
Caution is also needed with alpha-blockers, other antihypertensive medicines, and substantial alcohol intake, because these combinations may increase the risk of hypotension. Official labeling also warns about prolonged erection, priapism, sudden vision loss related to optic nerve injury, and sudden hearing loss. Patients with severe hepatic or renal impairment are generally not considered suitable candidates according to official labeling.
Possible Side Effects
Commonly reported adverse effects include headache, flushing, nasal congestion, nasopharyngitis, and back pain. Other reported effects include dizziness, dyspepsia, nausea, diarrhea, upper respiratory infection, bronchitis, sinusitis, and rash.
Serious but less common reactions can include prolonged erection or priapism, severe blood pressure lowering, and visual or hearing disturbances. Any persistent or severe adverse effect requires prompt medical evaluation.
Scientific Evidence
Human clinical studies and systematic reviews have found that avanafil improves erectile function compared with placebo, with a generally acceptable tolerability profile in studied populations. A randomized multicenter trial also found avanafil and sildenafil to be well tolerated, with headache the most common adverse event reported. Review-level evidence suggests avanafil is an effective PDE5 inhibitor option for erectile dysfunction, although comparative advantages over other agents are not uniformly established.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, product labeling, or individual assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration. STENDRA (avanafil) tablets, for oral use — prescribing information. View official prescribing information
- DailyMed / U.S. National Library of Medicine. AVANAFIL tablets, for oral use — label information. View official drug label
- European Medicines Agency. Spedra (avanafil) — European public assessment summary. View EMA medicine overview
- Manish Kumar et al. Efficacy and safety of avanafil as compared with sildenafil in the treatment of erectile dysfunction: A randomized, double blind, multicenter clinical trial. International Journal of Urology, 2022. View scientific article
- Qingqing Li et al. Avanafil for male erectile dysfunction: a systematic review and meta-analysis. Asian Journal of Andrology, 2014. View scientific article
